Bausch + Lomb completed the acquisition of XIIDRA from Novartis for $2.5bn.

Bausch + Lomb, an optical brand, completed the acquisition of XIIDRA, a non-steroid eye drop, from Novartis, a pharmaceutical company, for $2.5bn. “We expect to quickly take a leading position in the growing prescription dry eye category with the XIIDRA acquisition and MIEBO launch and, importantly, help the millions of patients not currently receiving adequate treatment for dry eye disease,” Brent Saunders, Bausch + Lomb Chairman and CEO.